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Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has been defined as an 
acute, clinically significant deterioration that develops within less than 1 month without 
obvious clinical cause like fluid overload, left heart failure, or pulmonary embolism. 
Pathophysiologically, damage of the alveoli is the predominant feature of AE-IPF which 
manifests histopathologically as diffuse alveolar damage and radiologically as diffuse, 
bilateral ground-glass opacification on high-resolution computed tomography. A grow-
ing body of literature now focuses on acute exacerbations of interstitial lung disease 
(AE-ILD) other than idiopathic pulmonary fibrosis. Based on a shared pathophysiology 
it is generally accepted that AE-ILD can affect all patients with interstitial lung disease 
(ILD) but apparently occurs more frequently in patients with an underlying usual interstitial 
pneumonia pattern. The etiology of AE-ILD is not fully understood, but there are distinct 
risk factors and triggers like infection, mechanical stress, and microaspiration. In general, 
AE-ILD has a poor prognosis and is associated with a high mortality within 6–12 months. 
Although there is a lack of evidence based data, in clinical practice, AE-ILD is often 
treated with a high dose corticosteroid therapy and antibiotics. This article aims to 
provide a summary of the clinical features, diagnosis, management, and prognosis of 
AE-ILD as well as an update on the current developments in the field.
Keywords: acute exacerbation, interstitial lung disease, idiopathic pulmonary fibrosis, definition, diagnosis, 
management
iNTRODUCTiON
Interstitial lung diseases (ILD) are a heterogeneous group of diseases. Despite various types of clini-
cal presentation, disease progression, and prognosis, the common feature in most ILDs is a fibrotic 
destruction of the lung parenchyma. Within the clinical course of ILD, an acute exacerbation [acute 
exacerbations of interstitial lung disease (AE-ILD)] can occur at any time and is associated with 
significant morbidity and mortality (1–5). Initially, AE-ILD was described in idiopathic pulmonary 
Abbreviations: AE-CTD, acute exacerbation of connective tissue disease related interstitial lung disease; AE-HP, acute exac-
erbation of chronic hypersensitivity pneumonitis; AE-IIP, acute exacerbation of idiopathic interstitial pneumonia; AE-ILD, 
acute exacerbations of interstitial lung disease; AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; AE-NSIP, acute 
exacerbation of non-specific interstitial pneumonia; AE-RA, acute exacerbation of rheumatoid arthritis and interstitial lung 
disease; ALI, acute lung injury; BAL, bronchoalveolar lavage; CCL, CC-chemokine ligand; CTD-ILD, connective tissue-related 
interstitial lung disease; DAD, diffuse alveolar damage; DLCO, diffusing capacity of the lung for carbon monoxide; FVC, forced 
vital capacity; HP, hypersensitivity pneumonitis; HRCT, high-resolution computed tomography; HSP, heat shock protein; 
IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den 
Lungen-6; NSIP, non-specific interstitial pneumonia; RA-ILD, interstitial lung disease in patients with rheumatoid arthritis; 
UIP, usual interstitial pneumonia.
TAbLe 1 | Revised and previous definitions and diagnostic criteria for AE-IPF.
Diagnosis of Ae-iPF Revised diagnosis Previous diagnosis
Definition
An acute, clinically significant, respiratory deterioration 
characterized by evidence of new widespread alveolar 
abnormalities
An acute, clinically significant, respiratory deteriorartion of 
unidentifiable cause
Diagnostic criteria
 – Previous diagnosis Previous or concurrent diagnosis of IPF Previous or concurrent diagnosis of IPF
 – Clinical presentation Acute worsening or development of dyspnea typically of less 
than 1 month
Unexplained worsening or development of dyspnea within 
30 days
 – Computed tomography findings New bilateral ground-glass opacity and/or consolidation 
superimposed on a background pattern consistent with usual 
interstitial pneumonia (UIP) pattern
New bilateral ground-glass abnormality and/or consolidation 
superimposed on a background reticular or honeycomb pattern 
consistent with UIP pattern
 – Exclusion of differential diagnosis Deterioration not fully explained by cardiac failure or fluid 
overload
Exclusion of alternative causes, including left heart failure, 
pulmonary embolism and an identifiable cause of acute lung injury
 – Concomitant Infection No evidence of pulmonary infection by endotracheal aspirate or 
bronchoalveolar lavage
AEIPF, acute exacerbation of idiopathic pulmonary fibrosis; IPF, idiopathic pulmonary fibrosis.
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fibrosis (IPF), and according to the official American Thoracic 
Society/European Respiratory Society/Japanese Respiratory 
Society/Latin American Thoracic Society IPF guideline, an acute 
exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has been 
defined as an acute clinical worsening of dyspnea which develops 
within less than 1 month without an alternative etiology (6).
Pathophysiologically, AE-ILD resembles an acute lung injury 
(ALI), which presents histopathologically as diffuse alveolar 
damage (DAD) in most cases (7). However, DAD is not only found 
in autopsy studies of patients with IPF but also in patients with 
connective tissue-related ILD (CTD-ILD), idiopathic fibrotic 
non-specific interstitial pneumonia (NSIP), and chronic hyper-
sensitivity pneumonitis (HP) (8, 9). Besides the histopathological 
DAD, AE-ILD and ALI have more clinical features in common, 
such as an increased oxygen requirement and new bilateral 
infiltrates on high-resolution computed tomography (HRCT) 
(e.g., ground-glass opacification/consolidation) (10–12).
While AE-IPF is increasingly recognized better and is 
perceived as a severe event with high mortality, there is only a 
limited amount of clinical data on AE-ILD in non-IPF ILD. The 
aim of this review is to provide a summary of the definition, clini-
cal features, diagnosis, prognosis, and management of AE-ILD. 
Furthermore, this review will update the current developments 
in the field of AE-ILD not only in IPF but also in non-IPF ILD.
DeFiNiTiON
Especially in IPF, great efforts have been made to establish a clear 
definition and diagnosis criteria for AE-IPF (6, 10, 13). In 2007, 
the IPF Clinical Trials Network (IPFnet) described the clinical 
presentation, radiological and histopathological findings of 
AE-IPF and developed diagnostic criteria based on the published 
literature (13). Just recently, an international working group 
revised an update on the definition of AE-IPF (Table  1) (10). 
In this document, AE-IPF is defined by a clinically significant 
respiratory deterioration developing within typically less than 
1  month, accompanied by new radiologic abnormalities on 
HRCT such as diffuse, bilateral ground-glass opacification, and 
the absence of other obvious clinical causes like fluid overload, 
left heart failure, or pulmonary embolism (10). In contrast to the 
previous definition, the authors promote discrimination between 
a triggered AE-IPF (e.g., infection, post-procedural/postopera-
tive or drug toxicity) and an idiopathic AE-IPF, where no trigger 
is identified (10). The revised definition aims to be broader and 
thus allow more inclusion possibilities. In the event of a clinical 
deterioration with unknown cause, where the criteria for AE-IPF 
are not met, the term “suspected AE-IPF” can be used (10). 
This might be the case if there are only unilateral ground glass 
abnormalities on HRCT or if HRCT data are even missing (13).
CLiNCAL FeATUReS AND DiAGNOSTiC 
evALUATiON
Unfortunately, so far, there is no existing official definition of 
AE-ILD in non-IPF ILD. Since an AE-ILD in non-IPF patients 
resembles AE-IPF (14–16), in the clinical setting it might be 
reasonable to apply the definition of AE-IPF to all AE-ILD. Still, 
it should be pointed out, that the current definition of AE-IPF 
refers exclusively to IPF and that the authors of the working group 
report decided against a definition including other ILD (10).
The clinical presentation of AE-ILD is usually a rapid worsening 
of respiratory symptoms with increased dyspnea within less than 
1  month (10, 13). Additional findings can be cough, increased 
sputum production, fever, and flu-like symptoms (1, 14, 15, 17). 
Since many patients present with a severe hypoxemia in the arterial 
blood gas analysis and respiratory failure, admission to the intensive 
care unit and assisted ventilation is often required (13). Established 
criteria for a presenting abnormal gas exchange is a PaO2/FiO2 ratio 
<225 or a decrease in PaO2 of ≥10 mmHg over time (13).
FiGURe 1 | Diagnostic approach to acute exacerbation in interstitial lung disease. Adapted from Ref. (10). Abbreviation: ILD, interstitial lung disease; GGO, ground 
glass opacity; CT, computed tomography.
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Still, establishing the diagnosis of AE-ILD often comprises 
a challenge. In order to get to this diagnosis, various diagnostic 
tests should be performed and differential diagnosis like myocar-
dial infarction, pulmonary embolism, or fluid overload need to be 
excluded (Figure 1). An elementary part of the diagnosis is the 
HRCT, which should be carried out in all patients who are clini-
cally stable. The important finding in AE-ILD is newly developed, 
bilateral alveolar infiltrates like ground-glass opacification with 
or without consolidation on HRCT (Figure 2) (6, 14, 16). Three 
suggested HRCT abnormality patterns are peripheral, multifocal 
and diffuse ground glass, with the latter two being associated with 
histologically DAD (13, 18). Several studies have shown that the 
extent of disease on HRCT seems to be related with the clinical 
outcome (1, 19–21). If there is no previous HRCT scan available, 
FiGURe 2 | HRCT of an acute exacerbation in IPF. Axial HRCT of a patient with IPF at the time of an acute exacerbation shows extensive bilateral ground-glass 
opacification. Abbreviation: HRCT, high resolution computed tomography; IPF, idiopathic pulmonary fibrosis.
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bilateral ground-glass opacity and/or consolidation on a back-
ground of usual interstitial pneumonia (UIP) pattern is sufficient 
to confirm the radiographic diagnostic criteria of AE-IPF (10). 
The term “suspected AE-IPF” should be used if there are only 
unilateral ground glass abnormalities (13).
Histologically, most AE-ILDs are characterized by a DAD, 
while alternative histological appearances comprise organizing 
pneumonia, alveolar hemorrhage, and unspecific inflammatory 
changes (1, 13, 15, 22, 23). In early stages, the acute injury of the 
lung is characterized by an interstitial edema and hyaline mem-
branes (10). Furthermore, type II pneumocyte hyperplasia and 
fibroblast foci have been reported in biopsies/autopsies as well 
as squamous metaplasia and honeycombing with and without 
hyaline membranes (24).
It has been reported, that patients with AE-ILD present with 
elevated inflammatory laboratory values such as increased white 
blood cell count, elevated values of erythrocyte sedimentation 
rate, and C-reactive protein and increased lactate dehydrogenase 
(14, 23–25). Although bronchoalveolar lavage (BAL) is not done 
routinely in AE-ILD, it has also been shown that AE-IPF and AE-HP 
are associated with an increase in neutrophils in BAL (1, 9, 17, 24–27). 
Rarely, lymphocytosis has been observed (23, 28), and reactive type 
II cells hyperplasia has been dectected on BAL (24). Furthermore, 
BAL is still the subject of research in terms of investigating the 
pathogenesis of AE and identifying possible prognostic factors.
ePiDeMiOLOGY
Acute exacerbations of interstitial lung disease can occur at any 
time during the disease, and in some cases it can be the present-
ing manifestation of an ILD (1, 13, 17). The exact frequency is 
unknown and the reported incidence rates of AE-ILD broadly 
vary, most likely due to differences in definition, ILD-entity and 
disease severity (10, 29). Furthermore, due to incomplete clinical 
information, definite AE-ILD cannot be confirmed in some cases, 
although AE-ILD is the suspected and the most probable diagnosis 
(10). The impact of this relevant difference was investigated in a 
post hoc analysis of the STEP-IPF trail, where a definite AE-IPF 
occurred in 40 per 1,000 patient-years but combining definite and 
suspected AE-IPF raised the number to 200 per 1,000 patient-years 
(30). In a recently published central adjudication on three rand-
omized controlled trials, only 33.2% of the investigator-reported 
AE-IPF met the criteria (31). A meta-analysis of six randomized-
controlled clinical trials identified a weighted average of 41 AE-IPF 
per 1,000 patient-years (32). In the INPULSIS I and II trial, the 
1-year incidence of AE-IPF in the placebo-arm was 7.6% (33).
Compared to clinical trials, retrospective studies report even 
higher 1-year incidences of AE-IPF, ranging from 7 to 19.1% 
with highest risk in advanced IPF (1, 2, 34–36). Retrospective 
analyses of studies from the US and Japan identified the inci-
dences of AE-IPF in approximately 52 per 1,000 patient-years 
(37, 38). In a registry-based US study, the annual rate of AE in IPF 
was 133 per 1,000 patient-years (39).
There is much less data on the frequency of AE-ILD in non-IPF 
ILD compared to AE-IPF. However, the majority of studies indi-
cate that patients with IPF are at a higher risk for developing AE 
compared to non-IPF ILD (40–43). The estimated 1-year incidence 
of AE-NSIP is reported to be 4.2%, and the estimated 1-year inci-
dence of AE-CTD ranges from 1.25 to 3.3% (14, 16). Within CTD-
ILD, AE seems to be most common in patients with rheumatoid 
arthritis ILD (RA-ILD) (16). Since the frequency of a UIP pattern 
is higher in RA-ILD compared to other ILDs, the higher number 
of AE-RA may be explained by the observation that a UIP pattern 
per se is associated with a higher risk of AE-ILD. Thus, in patients 
with CTD-ILD and RA-ILD with UIP pattern, a 1-year incidence 
of 5.6 and 11.1% was found, respectively (14). Furthermore, the 
2-year incidence of AE-HP was 11.5% among patients with chronic 
HP and UIP-like lesions on surgical biopsies (9).
Moreover, ethnicity may play a role, since AE-ILD were 
initially observed and reported in Japan and Korea, and the lit-
erature still is dominated by reports from Asian countries (1, 14, 
19, 35). However, two randomized, controlled studies did not 
support this observation (33, 44, 45).
PATHOGeNeSiS AND eTiOLOGY
The onset and development of an AE-ILD is unpredictable and 
until now, it is uncertain, whether an AE-ILD is triggered by an 
intrinsic factor causing a progression of the underlying disease 
or a response to an external factor (e.g., infection, aspiration, 
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pulmonary emboli, mechanical stretch) or both (6, 10). Most likely, 
environmental and genetic factors interact individually leading to 
AE-IPF in only a subset of patients (13). Concerning the parallels 
between AE-IPF and acute respiratory distress syndrome, the IPF 
lung may be generally more vulnerable to intrinsic and extrinsic 
triggers (10). Still, further research is needed to identify the 
underlying causes and potential biomarkers for AE-ILD.
epithelial injury
During AE-IPF, alveolar injury and loss of epithelial cell integrity 
may be involved leading to an increased fibrin production and 
remodeling (13, 46). Morphologically, this leads to neutrophilia 
in BAL and histopathological DAD (8, 17, 24). Neutrophilic 
processes are potentially transmitted via α-defensins, as they 
have been shown to be upregulated in patients with AE-IPF 
(47, 48). α-defensins belong to a family of antimicrobial and 
cytotoxic peptides contained in mammalian neutrophils (49, 50). 
Supporting the hypothesis of epithelial injury and proliferation 
during AE-IPF, a gene expression study of lung tissue detected 
an increased expression of cyclin A2 and α-defensins together 
with widespread apoptosis in lungs of patients suffering from 
AE-IPF in comparison to stable IPF and healthy controls (47). 
Furthermore, α-defensins were increased in the peripheral blood 
of patients with AE-IPF, suggesting a potential role as biomarker 
(47). In a later study including patients with idiopathic interstitial 
pneumonia (IIP), elevated plasma levels of α-defensins in AE-IIP 
compared to stable IIP were also seen, but they were not useful 
as biomarkers due to a lack of specificity (51). Therefore, further 
studies are needed to clarify the role of α-defensins as biomarker.
Moreover, it could be shown that fibrocytes, which are 
increased in stable IPF, are even more elevated during AE-IPF (52). 
Fibrocytes, CD45 and collagen-1 positive cells, are mesenchymal 
derived progenitor cells which can migrate into injured tissue and 
can differentiate to fibroblast-like cells playing a role in wound 
repair, tissue regeneration and pulmonary fibrosis (53, 54). Patients 
with fibrocytes >5% of total blood leukocytes had a significantly 
worse survival compared to patients with fibrocytes <5% (52).
Another theory includes the involvement of alternative, so 
called M2, activation of macrophages in AE-IPF. M2 macrophages 
play an important role in tumor progression and wound healing 
(55), and seem to be associated with ILD (56–58). It could be 
shown that the pro-inflammatory chemokines CXCL1 and 
Interleukin 8 (produced by classically activated macrophages) 
and the anti-inflammatory chemokines CC-chemokine ligand 
(CCL)2, CCL17, CCL18, CCL22, and Interleukin 1ra (produced 
by alternatively/M2 activated macrophages) were elevated in BAL 
of patients with AE-IPF in comparison to stable IPF (26). High 
CCL18 levels in BAL at baseline were further highly predictive for 
a future AE-IPF (26).
Further markers have been studied, including Krebs von den 
Lungen-6 (KL-6) and surfactant protein D, which were both 
identified to be elevated in AE-IPF compared to stable IPF (59) 
and KL-6 was also increased during the event of AE-HP (60). 
Furthermore, an elevated serum level of KL-6 at baseline was 
identified as a predictor for developing AE-ILD in both, IPF and 
combined pulmonary fibrosis and emphysema (34, 61). KL-6 is 
a mucin-like glycoprotein, which is mainly expressed in type II 
penumocytes and bronchial epithelial cells (62). In ILD, a high 
expression of KL-6 has been detected in regenerating type II cells 
likely being the primary source of serum KL-6 (63).
Increased levels of Interleukin 6 and Interleukin 8 were also 
detected in patients with AE-IPF and an increase in either of 
them was identified to be associated with worse outcome (59, 64). 
Total protein C, thrombomodulin, plasminogen activator inhibi-
tor 1 (59), and leptin (65) have also been shown to be elevated in 
the serum of patients with AE-IPF in comparison to stable IPF. 
In chronic HP, patients with elevated levels of KL-6 and surfactant 
protein D as well as increased neutrophils in the BAL fluid also 
have a higher risk for developing AE-HP.
Autoimmunity
Heat shock protein (HSP) 47 is a human collagen-specific 
molecular chaperone, which is involved in the early stages of 
biosynthesis and secretion of collagen molecules (66). In AE-IPF, 
it has been shown that HSP47 serum levels were significantly 
higher in comparison to stable IPF (67). Furthermore, immuno-
histochemical analysis detected more HSP47 expression in DAD 
than in UIP tissues (67). Interestingly, another study identified 
anti-HSP70 IgG autoantibodies in 25% of patients with IPF and 
anti-HSP70 positivity was associated with a higher mortality and 
risk for AE-IPF (68). Mortality among patients with positive anti-
HSP70 antibodies was significantly higher compared to patients 
with negative antibodies (68).
Supporting autoimmune involvement in AE-IPF, one study 
identified annexin 1 as an autoantigen which increased antibody 
production and T cell response in AE-IPF with the N-terminus 
of annexin 1 potentially playing a role in the pathogensis of 
AE-IPF (69).
infection
There is an increasing number of findings indicating that infec-
tion, both viral and bacterial, might be involved in some cases of 
AE-ILD. First, in a minority of patients with IIP suffering from 
AE-IIP, viral ribonucleic acid or a rise in specific immunoglobulins 
was detected by polymerase chain reaction or pan-viral microar-
ray (70–74). Moreover, changes in the respiratory microbiome 
were recently identified showing an increased bacterial burden in 
BAL during an AE-IPF (27). Patients with AE-IPF experienced a 
markable change in the respiratory microbiome with an increase 
in Campylobacter sp. and Stenotrophomonas sp., as well as a sig-
nificant decrease in Veillonella sp. compared to stable IPF (27). 
The hypothesis of an underlying infection is supported by the 
fact, that AE-IPF occurs more often between December and May 
(30, 75) and in the majority of studies an immunosuppressive 
therapy increases the risk for developing AE-IPF (30, 37, 76).
Microaspiration
Microaspiration might also have a connection to the develop-
ment of AE-ILD (10). In a post hoc analysis of the placebo-treated 
IPF patients in three clinical trials, none of the patients devel-
oping AE-IPF was on an anti-acid therapy (77). Furthermore, 
patients with AE-IPF had significantly higher levels of pepsin in 
BAL compared to stable controls, suggesting an involvement of 
occult aspiration (78).
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RiSK FACTORS
Several clinical risk factors are discussed playing a potentially 
crucial role in developing an AE-IPF. First of all, a functionally and 
clinically advanced stage of disease appears to be an important risk 
factor. In this context, a low forced vital capacity (FVC) seemed to 
be the most stable risk factor (2, 26, 30, 34, 35). Other clinical risk 
factors include a recent decline in FVC (35, 38, 79), a low diffusing 
capacity of the lung for carbon monoxide (DLCO) (9, 26, 30), a 
low total lung capacity (9), a low 6-min walking distance (30), 
an impaired baseline oxygenation (30, 38), an increased dyspnea 
(30, 35), and a previous AE-IPF (37, 79). However, it should also 
be considered, that the apparent association between advanced 
IPF and risk of AE-IPF may be biased by the fact that in advanced 
disease an AE may have more obvious clinical consequences, 
while it may even be overlooked in less advanced disease.
In 2007, Selman et al. discriminated IPF patients as rapid or 
slow progressors based on the duration of symptoms before first 
presentation (80). Although this study did not analyze AE-IPF, 
the authors stated that the rapid progression of AE-IPF does not 
correspond to an AE-IPF (80). Still, some links might be present as 
the rapid progressors showed a higher rate of fibroblast migration 
than slow progressors and survival was significantly reduced (80). 
Until now there is no proof for the theory that rapid progressors 
and AE-IPF could have a connection but obviously, there is not 
enough data in this field. Given the association between a recent 
decline of FVC and an increased risk of AE-IPF (35, 38, 79), it 
would be further interesting to acknowledge daily variability of 
FVC. In this context, daily home spirometry is a promising clini-
cal tool to follow the clinical course of IPF patients more closely 
and potentially detect AE-IPF earlier (81).
Although AE-ILD can occur in different histological forms 
of ILD, UIP-like lesions were identified to be associated with a 
higher risk for AE-ILD in patients with chronic HP and CTD-
ILD (9, 14). Additional risk factors including male gender (15), 
a co-existing pulmonary hypertension (36), coronary artery 
disease (30), a higher body-mass-index (35), and exposure 
to increased ozone and nitrogen dioxide levels (37) have been 
reported. Some studies observed a higher risk in former smokers 
(9, 34), but this finding is inconsistent (2, 26, 82). Similarly, there 
are different findings concerning age as a potential risk factor: in 
IPF, younger patients seem to be at a higher risk for AE-IPF (26), 
whereas a study on CTD-ILD identified higher age as a risk factor 
for developing AE-CTD (16).
In a retrospective study on patients with ILD and lung cancer 
undergoing chemotherapy, 21.9% of the patients experienced 
AE-ILD during the time from diagnosis to the end of the chemo-
therapy treatment period (83). The authors suggested tegafur–
gimeracil–oteracil potassium (S-1) and etoposide as relatively safe 
options in these patients. Moreover, there is one case-report about 
a patient with primary lung cancer and subclinical IPF, developing 
an AE-IPF after hypofractionated stereotactic radiotherapy (84).
A surgical biopsy is another important risk factor triggering 
AE-ILD. Whereas the incidence rates of developing an AE-ILD 
after a surgical biopsy for ILD-diagnosis finding are reported 
to be less than 2.5% (40, 41, 43, 85), AE-ILD after pulmonary 
resection due to lung cancer can occur in 3–32% (40, 86–88). 
A decreased FVC and DLCO seemed to be additional risk factors 
for patients with ILD developing a respiratory deterioration after 
lung surgery (43, 89). Pulmonary surgery itself seems to be a risk 
factor, but AE-ILD has also been reported in non-pulmonary 
surgery and throughout major surgeries the incidences was 3.3% 
in a study from Korea (90, 91). In IPF, there might be an associa-
tion between AE-IPF and BAL, as few, individual cases of AE-IPF 
following BAL exist (92, 93). Furthermore, as this will become 
increasingly important in the future, the risk of AE-ILD after 
cryobiopsy needs to be investigated. However, data in this field 
is still limited and so far, only single cases of AE-ILD following 
cyrobiopsy have been reported (94, 95).
PROGNOSiS
Acute exacerbations of interstitial lung disease is a life- 
threatening event and the mortality rate is high. It is assumed 
that between 35 and 46% of deaths in IPF are caused by AE-IPF 
(35, 96, 97). In a large number of studies, the in-hospital mortal-
ity in AE-IPF is estimated over 50% (1–4, 17, 19, 20, 36, 70, 98) 
and the median survival after AE-IPF is between 1 and 4 months 
(2, 36, 75, 82). In IPF, the 1-month mortality ranges between 37 
and 53% (37, 99), and the 3-month mortality rate ranges from 
63.8 to 73.7% (5, 19, 99). The existing data suggest that patients 
with IPF have a worse survival compared to ILD patients other 
than IPF; nonetheless, AE-ILD is also fatal in non-IPF ILD 
(5, 74). In a study including IPF and non-IPF patients, the overall 
survival after admission for AE-ILD was 67% at 1 month and 
40% at 3 months (4). Similarly to IPF, the highest overall mortal-
ity rate of AE-ILD is seen in AE-HP (75–100% mortality) (9, 15). 
Mortality of AE-ILD in other ILDs ranges from 34 to 83% (5, 16).
Some potential prognostic factors have been identified. First 
of all, lower baseline pulmonary function parameters (FVC and 
DLCO) as well as a more impaired oxygenation are associated 
with a worse outcome in AE-IPF (2, 35, 75). Furthermore, a 
higher fibrosis score or more extensive disease on HRCT seems 
to be of prognostic relevance (1, 19–21). A lymphocytosis >15% 
in the BAL might be another prognostic factor for a favorable 
outcome in patients with AE-IIP (28). Several markers in the 
blood could also be potential prognostic markers including 
lactate dehydrogenase (9, 19, 75), C-reactive protein (2), KL-6 
(19, 21), circulating fibrocytes (52), and anti-HSP70 autoantibod-
ies (68). Just recently, Kishaba et al. developed a staging system 
for AE-IPF, which includes some of these prognostic factors (19).
TReATMeNT
So far, there is a lack of evidence based data on effective thera-
pies in AE-ILD. In clinical practice, AE-ILD is often treated 
with high-dose systemic corticosteroid therapy and antibiotics 
(9, 14, 16). In AE-IPF, the current international guidelines give 
a weak recommendation on the treatment with corticosteroids 
emphasizing that this recommendation is based on anecdotal 
reports of benefit and the high overall mortality in AE-IPF 
(6). The authors further point out, that there was a consensus 
to promote supportive care as an important therapy strategy 
(6). This includes palliation of symptoms, e.g., with opioids, 
TAbLe 2 | Medical treatment of AE-IPF other than high-dose intravenous corticosteroids mono therapy.
Treatment Reference Study design Number of 
patients 
Treatment/intervention Clinical outcome
Tacrolimus Horita et al. (82) Single-center, 
retrospective study
15 Steroids mono versus combination 
steroids plus tacrolimus
Significantly better survival in 
tacrolimus-group
Cyclosporine Inase et al. (102) Single-center, 
retrospective study
14 Steroids mono versus steroids 
followed by cyclosporine
Cyclosporine seemed to prevent 
re-exacerbation and improve survival 
(no data on significance level)
Homma et al. (103) Retrospective study 44 Effect of treatment with steroids 
mono versus steroids plus 
cyclosporine before AE-IPF
Significantly better survival in 
cyclosporine-group
Sakamoto et al. (104) Single-center, 
retrospective study
22 Steroids mono versus combination 
of steroids plus cyclosporine
Significantly better survival in 
cyclosporine-group
Rituximab Donahoe et al. (105) Pilot- phase I/II-study; 
historical controls
31 Steroids mono versus combination 
of steroids plus rituximab/
therapeutic plasma exchanges and 
IVIG in severely ill IPF
Significantly better 1-year survival  
in rituximab group
PMX Seo et al. (99) Open-label pilot trial 6 Combination of steroids plus PMX Potential beneficial effect of treatment 
with PMX
Abe et al. (106) Multi-center, 
retrospective study
160 Combination of steroids plus PMX PMX improved oxygenation and may 
improve survival in IP patients with AE
Abe et al. (107) Single-center, 
retrospective study
45 Steroids mono versus combination 
of steroids plus PMX
PMX treatment significantly improved 
oxygenation
Oishi et al. (108) Single-center, 
retrospective study
50 Steroids mono versus combination 
of steroids plus PMX
Significantly better 1-year survival  
in PMX group
Oishi et al. (109) Single-center, 
retrospective study
26 Stable IPF and healthy controls 
versus combination of steroids plus 
PMX in AE-IPF 
PMX treatment significantly improved 
oxygenation
Thrombomodulin i.v. Isshiki et al. (110) Single-center, 
retrospective study
41 Steroids mono versus combination 
of steroids plus recombinant human 
soluble thrombomodulin
Thrombomodulin treatment  
significantly improved 3-month  
survival
Kataoka et al. (112) Single-center, 
retrospective study
40 Combination of steroids and 
cyclosporine versus combination 
of steroids and cyclosporin plus 
recombinant human soluble 
thrombomodulin
Thrombomodulin treatment  
significantly improved 3-month  
survival
Tsushima et al. (111) Single-center, combined 
prospective and 
retrospective study
20 Combination of steroids plus 
recombinant human soluble 
thrombomodulin
Thrombomodulin treatment  
significantly improved oxygenation
Hayakawa et al. (113) Single arm, non-
randomized prospective 
clinical trial; historical 
controls
23 Steroids mono versus combination 
of steroids plus recombinant human 
soluble thrombomodulin
Thrombomodulin plus steroid pulse 
therapy improved oxygenation and  
may improve overall survival
Abe et al. (114) Single-center, 
prospective, non-
randomized study
22 Steroids mono versus combination 
of steroids plus recombinant human 
soluble thrombomodulin
Thrombomodulin treatment  
significantly improved 3-month  
survival
Procalcitonin-guided 
antibiotic therapy
Ding et al. (115) Single-center, 
prospective, randomized 
study
68 Clinically guided versus 
procalcitonin-guided antibiotic 
therapy
Procalcitonin-guided antibiotic  
therapy had no benefits on survival
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and supply of oxygen in hypoxemia. Still, there are different 
opinions on the length of supportive care, and regarding the 
use of mechanical ventilation (10). Based on an estimated 
90% in-hospital mortality, the international guidelines on the 
management of IPF make a weak recommendation against the 
use of mechanical ventilation in the case of respiratory failure 
due to the underlying lung disease (6). The authors point out 
that this decision has to be made case-by-case together with the 
physician, the patient, and the family and in accordance with the 
individual goals of care (6). As a bridge to lung transplantation, 
mechanical ventilation, or extra-corporal membrane oxyge-
nation may be appropriate and successful in selected patients 
(6, 100). In a recent retrospective cohort study, the mortality rate 
in IPF patients undergoing mechanical ventilation significantly 
decreased from 58.4% in 2006 to 49.3% in 2012 (101). This 
reminds us to carefully analyze every single patient before a 
decision for or against mechanical ventilation is taken.
Several studies on different therapy regimens in AE-IPF, other 
than high-dose intravenous corticosteroids mono, have been 
published (Table 2). In smaller, observational studies, it could be 
(Continued )
Treatment Reference Study design Number of 
patients 
Treatment/intervention Clinical outcome
Cyclophosphamide Akira et at (20) Single-center, 
retrospective study
58 Steroids mono and combination 
of steroids mono plus 
cyclophosphamid
No data on treatment-related outcome
Fujimoto et al. (21) Multi-institutional, 
retrospective study
60 Steroids plus cyclophosphamide 
and steroids plus cyclosporine
No data on treatment-related outcome
Yokoyama et al. (116) Single-center, 
retrospective study
11 Steroids mono and combination 
of steroids mono plus 
cyclophosphamide and combination 
of steroids mono plus cyclosporine
No data on treatment-related outcome
AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; IPF, idiopathic pulmonary fibrosis; i.v., intravenous; IVIG, intravenous immunoglobulin; PMX, polymyxin B-immobilized 
fiber column.
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shown that the combination of a steroid-pulse therapy with oral 
tacrolimus (82) or cyclosporine (102–104) was superior to the 
corticosteroid mono therapy in terms of prognosis in IPF. Other 
studies identified a positive effect of a treatment with rituximab 
with plasma exchange and intravenous immunoglobulin (105), 
polymyxin B-immoblilized fiber column perfusion (99, 106–109), 
and intra-venous thrombomodulin (110–114). Still, the benefits 
seen in these studies have to be critically assessed since these 
were all observational studies with either a historical control 
or a parallel, untreated control arm, potentially excluding very 
ill patients from the experimental arm (10). One randomized 
trial investigated the benefit of a procalcitonin-guided antibiotic 
therapy compared to a clinical-driven antibiotic therapy but 
no difference in mechanical ventilation and mortality was seen 
(115). Several studies reported about a combination therapy of 
corticosteroids with other immunosuppressant drugs like cyclo-
phosphamide, but it remains unclear whether this is beneficial 
(20, 21, 116).
Currently, there are indications that an anti-acid therapy 
could have a protective effect against AE-IPF, as in an analysis 
of patients from the placebo arm of three large clinical trials, an 
anti-acid therapy was reported to have a potentially preventive 
effect on the development of AE-IPF (77). The same potentially 
preventive effect applies for antifibrotic drugs, although, so far, 
there is no sufficient data on whether an antifibrotic therapy 
with nintedanib or pirfenidone should be paused or continued 
in the event of an AE-IPF. In a phase II trial, patients receiving 
pirfenidone had a significant reduction in AE-IPF compared to 
placebo (117). However, a subsequent phase II trial could not 
reproduce this finding (44). After AE-IPF was not included as an 
endpoint in the three phase III trials ASCEND and CAPACITY 
(118, 119), a pooled analysis recently showed that patients 
receiving pirfenidone had a lower risk for respiratory-related 
hospitalization compared to healthy controls (120). Interestingly, 
there is data that the perioperative use of pirfenidone might 
prevent postoperative AE-IPF (121). In contrast to pirfenidone, 
AE-IPF was consequently included in the nintedanib clinical 
study program as a key secondary endpoint; however, the role of 
nintedanib on AE-IPF needs to be fully understood. Whereas the 
phase II trial of nintedanib identified a delay in time to the first 
investigator-reported AE in the nintedanib arm (122), only one of 
the two INPULSIS phase III twin-trials showed a significant effect 
of nintedanib on AE-IPF (33). Pooled analysis of the data showed 
a highly significant prolongation of the time to first AE in IPF 
due to treatment with nintedanib, thus confirming its preventive 
effect (45, 123). Still, at this point, more data is needed to validate 
the effect of pirfenidone and nintedanib in AE-ILD.
Apart from these potentially effective therapeutic approaches, 
there are a number of drugs that seem to have no preventive effect 
on AE-IPF, including acetylcystein mono therapy (124), sildenafil 
(125), bosentan (126), interferon-gamma 1b (127), warfarin 
(128), ambrisentan (129), and imatinib (130). A combination 
“triple” therapy (prednisone, azathioprine and acetylcysteine), 
might even increase the risk for developing AE-IPF (131).
As in AE-IPF, AE-ILD in non-IPF ILD is often treated with 
a high dose, systemic corticosteroid therapy together with 
broad-spectrum antibiotics (9, 14, 16). There are some studies 
additionally using cyclosporine A or cyclophosphamide, but there 
are no reports on whether there was any benefit in these therapies 
(9, 16). Similar to IPF, treatment with intra-venous thrombomo-
dulin significantly improved 3-month survival in AE-NSIP (114).
In order to address all therapeutic approaches in this con-
text, one study should be mentioned focusing on a non-steroid 
approach in AE-IPF: in the event of AE-IPF, prior immuno-
suppression was immediately stopped and patients were only 
treated with best supportive care and broad-spectrum antibiot-
ics (132). The median survival of all patients was 1.73 months. 
Analyzing the single event of AE-IPF, 50% of AE-IPF episodes 
were survived. Overall, 35.3% of the patients survived AE-IPF 
and the 1-year survival of the survivors was 83%. Interestingly, 
patients who had never been treated with immunosuppressant 
drugs before had a significantly better survival. The 1-year 
survival in the “never treated” group was 65%, whereas the 
patients, who had a history of immunosuppression, had a 1-year 
survival of 17%. Unfortunately, no comparison with a high-dose 
steroid therapy during AE-IPF was investigated in the study. 
Nevertheless, this underlines again the lack of evidence based 
data on therapy strategies in AE-ILD and the necessity for 
further studies in this field.
FUTURe
Acute exacerbations of interstitial lung diseases are severe events 
with a high mortality rate. Therefore, it is important to gain further 
TAbLe 2 | Continued
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knowledge in this field. As it has been shown that in IPF, an early 
referral to a specialized center is crucial for survival in general 
(133), in AE-ILD an early diagnosis and referral might also be 
important for the patients’ prognosis. Therefore, effort should be 
made to detect early signs of AE-ILD and identify patients who 
are at a higher risk for developing AE-ILD.
Potential treatment options should be studied in randomized, 
controlled trials. The currently revised definition of AE-IPF will 
hopefully allow a more uniform diagnosis, which will help to con-
duct well designed clinical trials in IPF (10). However, it should 
be emphasized that, even if it largely follows the framework of 
AE-IPF guidelines, an official, uniform definition for AE-ILD is 
needed in the future.
Biomarkers, which can be obtained in an easy and harmless 
way, are needed to identify patients at a higher risk for developing 
AE-ILD before symptoms and HRCT features are present. Since 
biomarkers in BAL might be difficult to obtain in a severely ill 
patient, serum markers are particularly interesting because of their 
easier accessibility. Furthermore, daily home spirometry might be 
a potential tool to understand the clinical course of AE-PF better 
and even possibly detecting AE-IPF in an early stage (81). There is 
evidence that home spirometry can potentially improve endpoint 
efficacy in clinical trials of IPF-therapeutics (134). Therefore, an 
effort should be made to design studies in that field analyzing the 
benefit of daily home spirometry in patients with ILD and help 
establishing home spirometry in clinical, daily routine.
CONCLUSiON
Acute exacerbations of interstitial lung disease is a life-threatening 
event with a high in-hospital mortality rate. The clinical pres-
entation of AE-ILD is similar in non-IPF and IPF, but AE-ILD 
in non-IPF ILD is less common and the clinical course is less 
fatal compared to IPF. The new working group report on AE-IPF 
supports that there are both, idiopathic and triggered AE 
(e.g., triggered by an infection) (10). So far, there is no evidence 
as to whether a triggered AE-ILD has a worse prognosis than an 
idiopathic AE-ILD. Due to the lack of evidence-based therapy 
options, more studies in this field are urgently needed.
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